Combination of chemotherapy and all-trans retinoic acid for the treatment KMT2A-rearranged infant acute lymphoblastic leukemia. Results of the MLL-Baby trial
- 23 September 2023
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 37 (11) , 2276-2281
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocolsLeukemia, 2020
- Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized StudyJournal of Clinical Oncology, 2019
- Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocolLeukemia, 2015
- Infant acute lymphoblastic leukemia: Lessons learned and future directionsCurrent Hematologic Malignancy Reports, 2009
- Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in RussiaLeukemia, 2008
- Contribution of All-Trans Retinoic Acid to Improved Early Relapse-Free Outcome in Infant Acute Lymphoblastic Leukemia Comparing to the Chemotherapy Alone.Blood, 2007
- Induction of acute lymphocytic leukemia differentiation by maintenance therapyLeukemia, 2007
- A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trialThe Lancet, 2007
- MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemiaNature Genetics, 2001
- Treatment Outcome and Prognostic Factors for Infants With Acute Lymphoblastic Leukemia Treated on Two Consecutive Trials of the Children's Cancer GroupJournal of Clinical Oncology, 1999